Continuous glucose monitoring reveals frequent dysglycaemia in very low birth weight infants nearing term age, with male sex ...

The printed cells remained alive and functional in test tubes for up to three weeks, maintaining strong insulin responses to glucose and showing real potential for future clinical use, the researchers ...

Type 1 diabetes affects over 8 million people around the world. It’s a lifelong condition that occurs when the immune system ...

IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Researchers at a recent American Diabetes Association meeting reported that efsitora, experimental once-weekly insulin, was comparable to daily insulins in nearly a thousand adults with type 2 ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...

Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time ...

The cure for diabetes is a life free from daily insulin injections. Based on that criterion, ten out of 12 people (83%) in a ...

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

Discover how zimislecel enables insulin independence in patients with Type 1 diabetes, showing strong efficacy in early ...